# A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621

> **NCT03595995** · PHASE2 · UNKNOWN · sponsor: **United BioPharma** · enrollment: 80 (estimated)

## Conditions studied

- Genital Herpes

## Interventions

- **BIOLOGICAL:** UB-621
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03595995
- **Lead sponsor:** United BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-01
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2022-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03595995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03595995, "A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03595995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*